Maternal Administration of Ethyl Pyruvate (EP) Extends Gestation, Decreases Uterine Contractions and Optimizes Newborn Outcomes through Neuroprotection
- 詳細技術說明
- None
- *Abstract
-
Pretermbirth is a significant public health burden worldwide. The underlyingbiological mechanisms remain unclear. There is currently no treatment toprolong pregnancy or provide fetal neuroprotection in the setting ofinflammatory preterm labor. Researchers at Nationwide Children’s Hospital haveidentified a role for ethyl pyruvate (EP) in preventing inflammation-inducedpreterm birth. EP is an emerging anti-inflammatory therapeutic proven safe forhumans. Additionally, researchers identified a neuroprotective role for EP inthe setting of acute intra-uterine inflammation. This technology represents anovel pharmaceutical intervention in preterm birth with the potential to lowerneonatal morbidity and mortality.
- *Inquiry
- Andrew CorrisThe Research Institute at Nationwide Children’s HospitalOffice of Technology Commercialization700 Children’s DriveColumbus, OH 43205T: (614) 355-1604 F: (614) 722-2716Andrew.Corris@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- 國家
- Not Available
- 申請號碼
- None
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
